Mina J. Bissell

Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

SCALABLE ORGANOTYPIC MODELS OF TUMOR DORMANCY

RHAMM, A CO-RECEPTOR AND ITS INTERACTIONS WITH OTHER RECEPTORS IN CANCER CELL MOTILITY AND THE IDENTIFICATION OF CANCER PROGNITOR CELL POPULATIONS

Peptides that stimulate subcutaneous adipogenesis

NON-CATALYTIC DOMAIN TARGETS IN MATRIX METALLOPROTEASE PROTEINS FOR CANCER THERAPIES

Peptides that stimulate subcutaneous adipogenesis

CELL CULTURE SCREEN FOR AGENTS THAT CONTROL ADIPOGENESIS AND MYOFIBROBLAST DIFFERENTIATION

Dynamic Assay for Maintenance and Disruption of Tissue Level Organization and Architecture

IDENTIFICATION OF INVASIVE AND SLOW-GROWING TUMORIGENIC CELL SUBSETS IN TUMORS

USE OF IL-17E FOR CANCER TREATMENT

14-3-3 sigma as a Biomarker of Basal Cancer

Detecting and treating breast cancer resistance to EGFR inhibitors

Modulation of Rhamm (CD168) for selective adipose tissue development

Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations

Method of increasing radiation sensitivity by inhibition of beta one integrin

TARGETING TNF-alpha CONVERTING ENZYME(TACE)- DEPENDENT GROWTH FACTOR SHEDDING IN CANCER THERAPY

IDENTIFICATION OF RAC1B AS A MARKER AND MEDIATOR OF METALLOPROTEINASE-INDUCED MALIGNANCY

Method of increasing radiation sensitivity by inhibition of beta one integrin

Design of novel assays based on the newly found role of dystroglycan and alpha-dystroglycan proteolysis in tumor cell growth

Drug screens based on the newly found role of dystroglycan proteolysis and restoration of dystroglycan function thereof